Single-cell RNA sequencing and AlphaFold 3 insights into cytokine signaling and its role in uveal melanoma

  • 0Department of Ophthalmology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.

|

|

Summary

This summary is machine-generated.

This study reveals distinct cell subtypes and prognostic biomarkers in uveal melanoma (UVM), a challenging eye cancer. Findings offer new avenues for targeted therapies and personalized treatment strategies to improve patient survival.

Area Of Science

  • Oncology
  • Immunology
  • Genomics

Background

  • Uveal melanoma (UVM) is an aggressive eye cancer with poor prognosis, especially in metastatic stages.
  • Understanding cellular heterogeneity is crucial for identifying new therapeutic targets.

Purpose Of The Study

  • To elucidate the cellular heterogeneity within UVM.
  • To identify prognostic biomarkers for UVM.
  • To explore potential therapeutic targets within the UVM microenvironment.

Main Methods

  • Single-cell RNA sequencing (scRNA-seq) was performed on primary and metastatic UVM samples.
  • A UVM-specific gene signature was developed and validated.
  • Protein structures were predicted using AlphaFold 3; T-cell dynamics and immune responses were analyzed.

Main Results

  • ScRNA-seq identified five major cell types and seven distinct subtypes in UVM.
  • Differential expression of cytokine signaling in immune-related genes (CSIRGs) was observed across subtypes.
  • A validated UVM-specific gene signature correlated with overall survival; increased myeloid-derived suppressor cells (MDSCs) were noted in metastatic UVM.

Conclusions

  • The study identified key cellular subtypes and prognostic biomarkers in UVM.
  • Insights into cytokine signaling and T-cell dynamics provide a basis for personalized therapeutic strategies.
  • Findings pave the way for improved treatment approaches to enhance patient outcomes.